Draupnir Bio announces the appointment of Anna Quattropani as Chief Discovery Officer

Draupnir Bio announced the appointment of Anna Quattropani, PhD, as Chief Discovery Officer. Anna brings over 20 years of experience in drug discovery and development. She will lead the internal and external drug discovery and medicinal chemistry efforts for Draupnir’s growing preclinical pipeline.

Draupnir Bio Aps is a biotechnology company that engages in developing cholesterol-lowering medicine. It was incorporated in 2017 and is based in Denmark.